The Rosen Law Firm announces that it is investigating potential securities claims against Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) resulting from allegations that the Company may have issued materially misleading business information to the investing public. On November 6, 2014, Salix Pharmaceuticals announced lower than expected third-quarter earnings and sales forecasts, as well as the sudden resignation of its Chief Financial Officer, Adam Derbyshire. In a conference call with analysts that same day, Chief Executive Officer, Carolyn Logan, disclosed that the Audit Committee is probing the Company's statements concerning its inventory levels. On this news, shares of Salix Pharmaceuticals fell sharply during intraday trading on November 7, 2014, damaging investors. The Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Salix Pharmaceuticals shareholders as a result of this adverse information. If you purchased Salix Pharmaceuticals stock on or before November 6, 2014 and wish to join the class action, please visit the website at http://rosenlegal.com/cases-431.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at firstname.lastname@example.org or email@example.com. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.